Concepedia

Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial

David Wirta, William Lipsky, Melissa Toyos, Joseph Martel, John D. Goosey, Anthony Verachtert, Shérif M. El-Harazi, Paul Karpecki, Marcello Allegretti, Giovanni Goisis,

BMC Ophthalmology · 2024 · 11 citations · 28 references

Open access

Abstract

NCT03982368; registered May 23, 2019.

References

28

CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

BMC Medicine · 2010 · 13.3K citations · Full text

The Lack of Association Between Signs and Symptoms in Patients With Dry Eye Disease

Kelly K. Nichols, Jason J. Nichols, G. Lynn Mitchell · Cornea · 2004 · 758 citations

A Test for Differences between Treatment Means When Several Dose Levels are Compared with a Zero Dose Control

D. A. Williams · Biometrics · 1971 · 743 citations

Pharmacology, Treatment Effect, Drug Monitoring +8

The Comparison of Several Dose Levels with a Zero Dose Control

D. A. Williams · Biometrics · 1972 · 726 citations

Precision Dosing, Pharmacology, Pharmacotherapy +7

The Relative Burden of Dry Eye in Patients’ Lives: Comparisons to a U.S. Normative Sample

Polyxane Mertzanis, Linda Abetz, Krithika Rajagopalan et al. · Investigative Ophthalmology & Visual Science · 2004 · 276 citations